drugset / Trial / NCT01928680
Phase II Study of Capecitabine and Cisplatin to Treat Metastatic Triple Negative Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
It is a phase II trial to explore the efficacy and safety of cisplatin plus capecitabine in anthracycline and taxane-pretreated metastatic triple negative breast cancer patients.
Timeline
- Start
- 2012-11
- Primary completion
- 2015-10
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | — |